Publicerat: 2021-07-14 07:38:03
SyntheticMR’s Q2 report was a setback from previous quarters’ strong trends with results being overall weaker-than-expected. However, with some of the disappointment being related to pandemic impacts and SyntheticMR holding several levers of growth throughout the year, we expect performance to improve when Covid-19-related headwinds eventually ease. Our new DCF-based fair value range is set at SEK 38-50 (previously SEK 42-56) per share.
Länk till analysen